CD43/Sialophorin Antibody (Bra7G), Novus Biologicals™

CD43/Sialophorin

0.2mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Unconjugated

Mouse

Immunology

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

6693

Immature pluripotent human leukemia K562 cells

Primary

Store at 4C.

Bra7G

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 1 - 2 ug/ml

Monoclonal

Purified

RUO

Human

CD43 antigen, CD43), Galactoglycoprotein, GALGP, Leukocyte sialoglycoprotein, Sialophorin, sialophorin (gpL115, leukosialin, CD43)

SPN

IgM κ

PEG purified

It recognizes a cell surface glycoprotein of 95/115/135kDa (depending upon the extent of glycosylation), identified as CD43 (Workshop V). Epitope of MAb Bra7G is clearly different from that of MAb DF-T1, called b as opposed to a for DF-T1. 70-90% of T-cell lymphomas and from 22-37% of B-cell lymphomas express CD43. No reactivity has been observed with reactive B-cells. So a B-lineage population that co-expresses CD43 is highly likely to be a malignant lymphoma, especially a low-grade lymphoma, rather than a reactive B-cell population. When CD43 antibody is used in combination with anti-CD20, effective immunophenotyping of the lymphomas in formalin-fixed tissues can be obtained. Co-staining of a lymphoid infiltrate with anti-CD20 and anti-CD43 argues against a reactive process and favors a diagnosis of lymphoma.